Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for the treatment of hepatocellular carcinoma, developed in collaboration with Moderna (MRNA). The abstract presents the first pre-clinical data on the development candidate targeting Glypican-3, a tumor-associated antigen commonly expressed in HCC. This novel off-the-shelf approach reprograms endogenous myeloid cells in vivo using lipid nanoparticles to deliver mRNA encoding CARs. The data show that this in vivo CAR-M therapy has significant potential as a treatment for GPC3+ solid tumors, including HCC.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics, Inc. (CARM) Q3 Earnings Cheat Sheet
- Leadership Transition at Carisma Therapeutics’ Board of Directors
- Alphabet upgraded, Boeing downgraded: Wall Street’s top analyst calls
- Carisma Therapeutics initiated with a Buy at EF Hutton
- Carisma Therapeutics and Moderna expand collaboration to develop CAR-M therapies